Safi Biotherapeutics Acquires EryPharm
Safi Biotherapeutics announced that it entered into an agreement to acquire all the assets of EryPharm, a Paris, France-based biotechnology company. According to data captured in the LevinPro HC database, this acquisition marks the sixth Biotechnology transaction of 2024. EryPharm, a spin-off of Prof. Luc Douay’s Sorbonne University team, is an innovative company for the industrial culture of red blood cells from stem cells. It achieved a breakthrough in the production of a new biological drug, the Cultured Red Blood Cells from Hematopoietic Stem Cells, which aims to supplement blood donation for blood transfusion. Safi Biotherapeutics is a pre-clinical stage blood cell... Read More »
Three Large Biotech Transactions Announced
On Monday, January 8, there was a flurry of activity in the Biotechnology sector. Three large, publicly-traded companies announced acquisitions in the space, representing the third, fourth and fifth Biotechnology transaction of 2024, respectively. Last year, there were 155 Biotechnology deals announced, according to data captured in the LevinPro HC database. Merck acquires Harpoon Therapeutics: Merck announced the acquisition of Harpoon Therapeutics through a subsidiary for an approximate total equity value of $680 million. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune... Read More »
Bristol Myers Squibb Buys Karuna Therapeutics for $14 Billion
Bristol Myers Squibb (BMS) and Karuna Therapeutics announced on December 22 that they have entered into a definitive merger agreement under which BMS will acquire Karuna. Under the terms of the merger agreement, BMS will acquire all outstanding shares of Karuna common stock for $330 per share in cash representing an approximately 53.4% premium to Karuna Therapeutic’s closing stock price on December 21, 2023. This represents a total equity value of approximately $14 billion, or $12.7 billion net of estimated cash acquired. Karuna Therapeutics is a biopharmaceutical company focused on transformative medicines for people living with psychiatric and neurological conditions.... Read More »
AstraZeneca Picks up Vaccine Developer Icosavax for $800 Million
AstraZeneca announced on December 12 that it is acquiring Icosavax, which develops a shot for respiratory syncytial virus (RSV), for $800 million in upfront cash. The deal value equates to $15 per share. Icosavax’s shareholders will also be in line for another $5 in cash per share, if certain regulatory and sale milestones are hit. Icosavax is a clinical-stage biopharmaceutical company leveraging its virus-like particles (VLPs) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. The company’s pipeline includes a phase 3-ready protein VLP... Read More »
AbbVie Acquires Cerevel Therapeutics for $8.7 Billion
AbbVie Inc. continues its shopping spree with yet another Boston-based biotechnology acquisition. The company announced that it will be acquiring Cerevel Therapeutics for approximately $8.7 billion. This transaction follows AbbVie’s acquisition of ImmunoGen Inc. for a total equity value of approximately $10.1 billion, announced on November 30, 2023. Founded in 2018, Cerevel Therapeutics researches treatments and therapeutics to treat neuroscience diseases. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
